Avenge Bio News Today

NATICK, Mass. and QUINCY, Mass., Nov. 20, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of

The fast pace of progress in endometrial cancer has taken a step forward with two trials underlining the benefit of immunotherapy plus chemo, while suggesting adding a PARP inhibitor could further boost outcomes.

The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,

Investegate announcements from NMD Pharma, Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Mike Heffernan appointed Chairman of NMD Pharma's Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen

/PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision...

Sanofi did not see the efficacy it wanted in mid-stage tests of a cytokine therapy from its $2.5 billion acquisition of Synthorx. While the pharmaceutical giant isn’t giving up on the drug, it said it will restart the molecule in a new Phase 1/2 program, a setback that will lead to a €1.6 billion financial writedown.

/PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision...

A treatment that combines cytokine "drug factory" implants with a checkpoint inhibitor drug eradicates advanced-stage mesothelioma tumors in mice in days.